Best Life: Special targeting for Melanoma
HACKENSACK, N.J. (Ivanhoe Newswire) – 98,000 Americans will be diagnosed with melanoma this year, and 7,000 will die from it.
New treatments, like immunotherapy and targeted therapies, increase a patient’s chances of survival.
Now, in a brand-new study, researchers say the order doctors deliver these cutting-edge treatments makes a difference.
For years, people spent hours in the sun, trying to get a healthy glow. These days, we know that exposure to UV rays can be a risk factor for cancer.
“Up until not that long ago, metastatic melanoma was a uniformly fatal disease. If you had it, you usually died of it within a few years,” Andrew Pecora, MD, Hackensack University Medical Center oncologist.
Now, doctors can treat metastatic melanoma in two ways: with immunotherapy – using a person’s immune system to fight cancer – or for patients with a specific gene mutation called the BRAF mutation – targeted therapy.
Doctors have been prescribing either to patients with the gene mutation. The DREAMSeq trial proved the order or sequence of the treatment matters.
“Patients who received immunotherapy first had a significantly better survival than patients who received targeted therapy first,” says Dr. Pecora.
Dr. Pecora also says the sequence of treatment – with immunotherapy first – should become the standard of care, which will result in more people being alive for five years or more.
If immunotherapy doesn’t work, doctors should then follow with targeted therapy.
Dr. Pecora says about 50 percent of metastatic melanoma patients have the BRAF gene, so this finding will have big implications for a lot of patients.
Contributors to this news report include: Cyndy McGrath, Producer; Kirk Manson, Videographer; Roque Correa, Editor.
Click here to sign up for our newsletter!
Click here to report a spelling or grammar error. Please include the headline.
Copyright 2023 WMC. All rights reserved.